# Obesity Treatment to Improve Diabetes

> **NCT05390307** · NA · COMPLETED · sponsor: **Dasman Diabetes Institute** · enrollment: 60 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Liraglutide / Semaglutide
- **DRUG:** Dapagliflozin
- **DRUG:** Liraglutide or Semaglutide / Dapagliflozin
- **DRUG:** Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition
- **OTHER:** Usual care

## Key facts

- **NCT ID:** NCT05390307
- **Lead sponsor:** Dasman Diabetes Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2024-01-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05390307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05390307, "Obesity Treatment to Improve Diabetes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05390307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*